Table 3.
PAH targeted medication around pregnancy.
| Case | CCB | PDE-5 | ERA | Anticoagulation | Diuretics | |
|---|---|---|---|---|---|---|
| 1.1 | Before | X | X | |||
| (27 y/o) | During | X | X | X | ||
| Childbed | X | X | X | |||
| 1.2 | Before | X | ||||
| (30 y/o) | During | X | ||||
| Childbed | X | X | ||||
| 2 | Before | X | X | |||
| (36 y/o) | During | X | X | |||
| Childbed | X | X | ||||
| 3.1 | Before | X | X | |||
| (26 y/o) | During | X | X | |||
| Childbed | X | X | X | |||
| 3.2 | Before | X | X | |||
| (31 y/o) | During | X | X | |||
| Childbed | X | X | X | |||
| 4 | Before | X | X | X | X | |
| (28 y/o) | During | X | * | X | X | |
| Childbed | X | * | X | |||
| 5 | Before | X | X | X | ||
| (29 y/o) | During | X | ** | X | ||
| Childbed | X | ** | X |
*
replacement of ERA with inhaled iloprost.
**
replacement of ERA with selexipag.
y/o, years old; CCB, calcium canal blocker; PDE-5-inhibitor, phosphodiesterase type 5 inhibitor; s.c., subcutaneous; ERA, endothelin receptor antagonist; AC, anticoagulation.